The Use of Beta 2-Agonists for the Treatment of Acute Respiratory Distress Syndrome

Brun-Buisson C Minelli C Bertolini G . Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004;30: 51–61.

Herridge MS Tansey CM Matté A . Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011;364: 1293–304.

The ARDS Definition Task Force. Acute Respiratory Distress Syndrome, The Berlin Definition. JAMA 2012;307: 2526–33.

Bassford CR Thickett DR Perkins GD . The rise and fall of β-agonists in the treatment of ARDS. Crit Care 2012;16: 208.

Perkins GD McAuley DF Thickett DR Gao F . The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173: 281–87.

Smith FG Perkins GD Gates S , for the BALTI-2 study investigators et al.. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012;379: 229–35.

Matthay MA Brower RG Carson S . Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184: 561–68.

Thomson T . β-Agonists for ARDS: a window into the dark side of adrenergic stimulation? Lancet 2011;379: 196–98.